-+ 0.00%
-+ 0.00%
-+ 0.00%

Nyxoah Reports Preliminary Q3 Global Net Sales Of ~€9.2M, Up 19% QoQ; Lowers FY26 Global Net Sales From €36M-€40M To €33M-€35M

Benzinga·10/19/2026 12:05:07
Listen to the news

Third Quarter 2026 – Preliminary Sales and Market Metrics

Financials
Global net revenue is expected to be approximately €9.2 million in the third quarter of 2026, which reflects 19% sequential growth over the second quarter of 2026
U.S. net revenue is expected to be approximately €6.7 million in the third quarter of 2026, which reflects 29% sequential growth over the second quarter of 2026
Leading U.S. commercial indicators
80 new surgeons trained in Q3, bringing the total to 342 surgeons trained
53 new accounts activated in Q3, bringing the total to 233 active high-volume accounts
447 patients actively under prior authorization entering Q4
Clinical and Regulatory
ACCCESS U.S. pivotal study met its co-primary efficacy endpoints and its safety endpoints in Complete Concentric Collapse (CCC) patients, with a 12-month AHI responder rate of 77.2% (p<0.001) and zero device- and procedure-related serious adverse events
Submitted a premarket approval (PMA) supplement to the FDA to expand Genio’s U.S. indication to CCC patients under Breakthrough Device Designation
Complete 12-month ACCCESS dataset presented at the International Surgical Sleep Society (ISSS) annual meeting, October 15-16, 2026
Liquidity
As of September 30, 2026, cash, cash equivalents and financial assets are expected to be approximately €77.0 million.

 

Revenue Guidance for the Full Year 2026

The Company now expects global net revenue for the full year 2026 to be in the range of €33 million to €35 million, compared to €36 million to €40 million previously.